J Korean Assoc Oral Maxillofac Surg.  2019 Feb;45(1):3-8. 10.5125/jkaoms.2019.45.1.3.

Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

• Nifosì AF
• Zuccarello M
• Nifosì L
• Hervas Saus V
• Nifosì G

• KMID: 2461485
• DOI: http://doi.org/10.5125/jkaoms.2019.45.1.3

Abstract

Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, dentist, and dental hygienist remains the most important aspect for the prevention, prompt recognition, and treatment of this pathology.

Keyword

Bone; Infection; Oral manifestations; Immunomodulation; Angiogenesis modulators

Reference

1. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2015; 22:151–165.

2. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006; 407:597–612.

3. Sun J, Sun Q, Brown MF, Dudgeon C, Chandler J, Xu X, et al. The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. PLoS One. 2012; 7:e43158.

4. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol. 2009; 20:600–601.

5. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012; 107:1665–1671.

6. Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 2010; 33:321–323.

7. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110:463–469.

8. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 2012; 16:952–957.

9. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer. 2018; 26:869–878.

10. Koch FP, Walter C, Hansen T, Jäger E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg. 2011; 15:63–66.

11. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113:e1–e3.

12. Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori. 2016; 102:Suppl 2. S69–S70.

13. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 2013; 71:1532–1540.

14. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289:1938–1942.

15. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia. 2003; 17:1713–1721.

16. Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg. 2017; 43:120–124.

17. Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018; 125:157–163.

18. Shen G, Ren H, Qiu T, Zhang Z, Zhao W, Yu X, et al. Mammalian target of rapamycin as a therapeutic target in osteoporosis. J Cell Physiol. 2018; 233:3929–3944.

19. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010; 1804:433–439.

20. Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013; 28:2392–2399.

21. Simone V, Ciavarella S, Brunetti O, Savonarola A, Cives M, Tucci M, et al. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer. 2015; 15:692.

22. Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg. 2013; 51:e302–e304.

23. Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, et al. Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol. 2017; 6:255–257.

24. Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma). 2013; 4:Suppl 2. 20–21.

25. Nifosì AF, Nifosì L, Nifosì G. Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus. SAJ Case Rep. 2017; 4:401.

26. Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017; 5:E34.

27. Magremanne M, Lahon M, De Ceulaer J, Reychler H. Unusual bevacizumab-related complication of an oral infection. J Oral Maxillofac Surg. 2013; 71:53–55.

28. Hartl DM, Bahleda R, Hollebecque A, Bosq J, Massard C, Soria JC. Bevacizumab-induced laryngeal necrosis. Ann Oncol. 2012; 23:276–278.

29. Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 2010; 103:772–775.

30. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008; 26:4037–4038.

31. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumabassociated osteonecrosis of the jaw. Ann Oncol. 2008; 19:2091–2092.

32. Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tetè S, Dolci M. Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol. 2009; 22:1121–1123.

33. Wynn RL. Bevacizumab (Avastin): an anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent. 2011; 59:410–413.

34. Dişel U, Beşen AA, Özyılkan Ö, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol. 2012; 48:e2–e3.

35. Katsenos S, Christophylakis C, Psathakis K. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab. Arch Bronconeumol. 2012; 48:187–220.

36. Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. 2013; 17:303–306.

37. Brunamonti Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF. Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol. 2012; 25:789–791.

38. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009; 76:209–211.

39. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009; 27:221–226.

40. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010; 122:181–188.

41. McArthur HL, Estilo C, Huryn J, Williams T, Fornier M, Traina TA, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 2008; 26:15 Suppl. 9588.

42. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, et al. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc. 2011; 142:506–513.

43. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg. 2012; 70:632–635.

44. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996; 93:14765–14770.

45. Bettini G, Blandamura S, Saia G, Bedogni A. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. 2012; 2012:pii: bcr2012007284.

46. Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, Dias RB, Prado Ribeiro AC, Brandão TB. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115:e32–e36.

47. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009; 9:263–271.

48. Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol. 2016; 7:E81–E87.

49. Ponzetti A, Pinta F, Spadi R, Mecca C, Fanchini L, Zanini M, et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori. 2016; 102:Suppl 2. S74–S77.

50. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther. 2007; 7:1245–1256.

51. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402:304–309.

52. Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol. 2015; 51:e100–e101.

53. Hujoel P, Barasch A, Cunha-Cruz J, Curro FA, Sung AH, Vena D, et al. Osteonecrosis of the jaw and oral hygiene: a case-control study from Condor Dental PBRN. J Dent Hyg. 2012; 86:32–33.

54. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc. 2011; 77:b147.

55. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30:3–23.